Novo Nordisk's (NVO) parent company, Novo Holdings, is expected to win EU antitrust approval for its pending $16.5 billion acquisition of US contract drug maker Catalent (CTLT), Reuters reported Friday, citing an unnamed person with direct knowledge of the matter.
The report said that Catalent is preparing senior management for the deal to go through.
The deal, crucial for boosting production of Novo Nordisk's blockbuster weight-loss drug Wegovy, awaits a final decision from the European Commission by Dec. 6.
Novo Nordisk, Catalent, European Commission did not immediately respond to requests for comment.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。